nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—Lenalidomide—hematologic cancer	0.208	0.608	CrCtD
Pomalidomide—CRBN—hematologic cancer	0.146	0.838	CbGaD
Pomalidomide—Thalidomide—hematologic cancer	0.134	0.392	CrCtD
Pomalidomide—Thalidomide—Lenalidomide—hematologic cancer	0.102	0.529	CrCrCtD
Pomalidomide—Lenalidomide—Thalidomide—hematologic cancer	0.0906	0.471	CrCrCtD
Pomalidomide—CRBN—Lenalidomide—hematologic cancer	0.0756	0.387	CbGbCtD
Pomalidomide—CRBN—Thalidomide—hematologic cancer	0.0404	0.206	CbGbCtD
Pomalidomide—TNF—hematologic cancer	0.0201	0.116	CbGaD
Pomalidomide—TNF—Thalidomide—hematologic cancer	0.0168	0.0857	CbGbCtD
Pomalidomide—ABCB1—hematologic cancer	0.00813	0.0467	CbGaD
Pomalidomide—PTGS2—Lenalidomide—hematologic cancer	0.00623	0.0318	CbGbCtD
Pomalidomide—CYP1A2—Anagrelide—hematologic cancer	0.00339	0.0173	CbGbCtD
Pomalidomide—PTGS2—Thalidomide—hematologic cancer	0.00333	0.017	CbGbCtD
Pomalidomide—PTGS2—Triamcinolone—hematologic cancer	0.00231	0.0118	CbGbCtD
Pomalidomide—ABCB1—Lenalidomide—hematologic cancer	0.00205	0.0105	CbGbCtD
Pomalidomide—PTGS2—Betamethasone—hematologic cancer	0.00198	0.0101	CbGbCtD
Pomalidomide—CYP1A2—Carmustine—hematologic cancer	0.00178	0.0091	CbGbCtD
Pomalidomide—PTGS2—ovarian follicle—hematologic cancer	0.00157	0.19	CbGeAlD
Pomalidomide—CYP1A2—Methoxsalen—hematologic cancer	0.00151	0.00774	CbGbCtD
Pomalidomide—CYP1A2—Bortezomib—hematologic cancer	0.00144	0.00736	CbGbCtD
Pomalidomide—PTGS2—Cisplatin—hematologic cancer	0.00142	0.00728	CbGbCtD
Pomalidomide—PTGS2—Etoposide—hematologic cancer	0.0014	0.00715	CbGbCtD
Pomalidomide—CYP1A2—Daunorubicin—hematologic cancer	0.00138	0.00704	CbGbCtD
Pomalidomide—CYP1A2—Alitretinoin—hematologic cancer	0.00135	0.0069	CbGbCtD
Pomalidomide—CYP1A2—Thalidomide—hematologic cancer	0.00125	0.00641	CbGbCtD
Pomalidomide—CYP3A4—Bexarotene—hematologic cancer	0.00123	0.00629	CbGbCtD
Pomalidomide—ABCB1—Daunorubicin—hematologic cancer	0.0012	0.00616	CbGbCtD
Pomalidomide—ABCB1—Alitretinoin—hematologic cancer	0.00118	0.00603	CbGbCtD
Pomalidomide—PTGS2—Dexamethasone—hematologic cancer	0.00115	0.00588	CbGbCtD
Pomalidomide—CYP3A4—Busulfan—hematologic cancer	0.00114	0.00585	CbGbCtD
Pomalidomide—CYP3A4—Lomustine—hematologic cancer	0.00114	0.00585	CbGbCtD
Pomalidomide—CYP1A2—Dacarbazine—hematologic cancer	0.00108	0.00551	CbGbCtD
Pomalidomide—CYP1A2—Imatinib—hematologic cancer	0.00106	0.00539	CbGbCtD
Pomalidomide—CYP3A4—Thiotepa—hematologic cancer	0.00102	0.00521	CbGbCtD
Pomalidomide—TNF—blood—hematologic cancer	0.000966	0.117	CbGeAlD
Pomalidomide—ABCB1—Imatinib—hematologic cancer	0.000923	0.00472	CbGbCtD
Pomalidomide—CYP1A2—Dasatinib—hematologic cancer	0.000847	0.00433	CbGbCtD
Pomalidomide—ABCB1—Nilotinib—hematologic cancer	0.000838	0.00429	CbGbCtD
Pomalidomide—ABCB1—Vinorelbine—hematologic cancer	0.000831	0.00425	CbGbCtD
Pomalidomide—CYP3A4—Methoxsalen—hematologic cancer	0.000793	0.00405	CbGbCtD
Pomalidomide—CYP3A4—Bortezomib—hematologic cancer	0.000754	0.00386	CbGbCtD
Pomalidomide—ABCB1—Dasatinib—hematologic cancer	0.000741	0.00379	CbGbCtD
Pomalidomide—ABCB1—Mitoxantrone—hematologic cancer	0.000732	0.00374	CbGbCtD
Pomalidomide—CYP3A4—Daunorubicin—hematologic cancer	0.000722	0.00369	CbGbCtD
Pomalidomide—Lenalidomide—CRBN—hematologic cancer	0.000722	0.414	CrCbGaD
Pomalidomide—CRBN—hematopoietic system—hematologic cancer	0.000697	0.0843	CbGeAlD
Pomalidomide—ABCB1—Betamethasone—hematologic cancer	0.000652	0.00333	CbGbCtD
Pomalidomide—ABCB1—Gemcitabine—hematologic cancer	0.000647	0.00331	CbGbCtD
Pomalidomide—ABCB1—Prednisolone—hematologic cancer	0.000644	0.00329	CbGbCtD
Pomalidomide—CYP3A4—Cytarabine—hematologic cancer	0.000637	0.00325	CbGbCtD
Pomalidomide—CYP3A4—Teniposide—hematologic cancer	0.000627	0.00321	CbGbCtD
Pomalidomide—ABCB1—Prednisone—hematologic cancer	0.000608	0.00311	CbGbCtD
Pomalidomide—TNF—lymph node—hematologic cancer	0.000579	0.0701	CbGeAlD
Pomalidomide—CYP3A4—Ifosfamide—hematologic cancer	0.000579	0.00296	CbGbCtD
Pomalidomide—ABCB1—Irinotecan—hematologic cancer	0.000576	0.00295	CbGbCtD
Pomalidomide—CYP3A4—Imatinib—hematologic cancer	0.000553	0.00283	CbGbCtD
Pomalidomide—CRBN—gonad—hematologic cancer	0.00053	0.0641	CbGeAlD
Pomalidomide—CYP1A2—Etoposide—hematologic cancer	0.000528	0.0027	CbGbCtD
Pomalidomide—CYP3A4—Ruxolitinib—hematologic cancer	0.000521	0.00266	CbGbCtD
Pomalidomide—ABCB1—Vinblastine—hematologic cancer	0.000512	0.00262	CbGbCtD
Pomalidomide—ABCB1—Vincristine—hematologic cancer	0.000504	0.00257	CbGbCtD
Pomalidomide—CYP3A4—Nilotinib—hematologic cancer	0.000502	0.00257	CbGbCtD
Pomalidomide—CYP3A4—Vinorelbine—hematologic cancer	0.000498	0.00255	CbGbCtD
Pomalidomide—Lenalidomide—TNFSF11—hematologic cancer	0.000487	0.28	CrCbGaD
Pomalidomide—ABCB1—Cisplatin—hematologic cancer	0.00047	0.0024	CbGbCtD
Pomalidomide—CRBN—blood—hematologic cancer	0.000462	0.0558	CbGeAlD
Pomalidomide—ABCB1—Etoposide—hematologic cancer	0.000462	0.00236	CbGbCtD
Pomalidomide—CYP3A4—Triamcinolone—hematologic cancer	0.000456	0.00233	CbGbCtD
Pomalidomide—CRBN—bone marrow—hematologic cancer	0.000447	0.054	CbGeAlD
Pomalidomide—CYP3A4—Dasatinib—hematologic cancer	0.000444	0.00227	CbGbCtD
Pomalidomide—CYP3A4—Mitoxantrone—hematologic cancer	0.000439	0.00224	CbGbCtD
Pomalidomide—Thalidomide—CRBN—hematologic cancer	0.000432	0.248	CrCbGaD
Pomalidomide—CRBN—lung—hematologic cancer	0.000405	0.049	CbGeAlD
Pomalidomide—CYP3A4—Betamethasone—hematologic cancer	0.000391	0.002	CbGbCtD
Pomalidomide—CYP3A4—Prednisolone—hematologic cancer	0.000386	0.00197	CbGbCtD
Pomalidomide—CRBN—testis—hematologic cancer	0.000382	0.0462	CbGeAlD
Pomalidomide—ABCB1—Dexamethasone—hematologic cancer	0.000379	0.00194	CbGbCtD
Pomalidomide—CYP3A4—Prednisone—hematologic cancer	0.000364	0.00186	CbGbCtD
Pomalidomide—CYP3A4—Irinotecan—hematologic cancer	0.000345	0.00177	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—hematologic cancer	0.000315	0.00161	CbGbCtD
Pomalidomide—CYP3A4—Vinblastine—hematologic cancer	0.000307	0.00157	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—hematologic cancer	0.000305	0.00156	CbGbCtD
Pomalidomide—CYP3A4—Vincristine—hematologic cancer	0.000302	0.00154	CbGbCtD
Pomalidomide—CRBN—lymph node—hematologic cancer	0.000277	0.0335	CbGeAlD
Pomalidomide—CYP3A4—Etoposide—hematologic cancer	0.000277	0.00141	CbGbCtD
Pomalidomide—CYP1A2—hematopoietic system—hematologic cancer	0.000229	0.0277	CbGeAlD
Pomalidomide—CYP3A4—Dexamethasone—hematologic cancer	0.000227	0.00116	CbGbCtD
Pomalidomide—PTGS2—hematopoietic system—hematologic cancer	0.00019	0.023	CbGeAlD
Pomalidomide—CYP3A4—Doxorubicin—hematologic cancer	0.000189	0.000964	CbGbCtD
Pomalidomide—CYP3A4—hematopoietic system—hematologic cancer	0.000166	0.0201	CbGeAlD
Pomalidomide—CYP1A2—blood—hematologic cancer	0.000152	0.0184	CbGeAlD
Pomalidomide—CYP1A2—lung—hematologic cancer	0.000133	0.0161	CbGeAlD
Pomalidomide—PTGS2—blood—hematologic cancer	0.000126	0.0152	CbGeAlD
Pomalidomide—PTGS2—bone marrow—hematologic cancer	0.000122	0.0147	CbGeAlD
Pomalidomide—ABCB1—hematopoietic system—hematologic cancer	0.000117	0.0142	CbGeAlD
Pomalidomide—PTGS2—lung—hematologic cancer	0.00011	0.0133	CbGeAlD
Pomalidomide—CYP3A4—blood—hematologic cancer	0.00011	0.0133	CbGeAlD
Pomalidomide—PTGS2—Fluocinonide—Betamethasone—hematologic cancer	9.98e-05	0.209	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Dexamethasone—hematologic cancer	9.98e-05	0.209	CbGdCrCtD
Pomalidomide—PTGS2—Fluocinonide—Triamcinolone—hematologic cancer	9.75e-05	0.205	CbGdCrCtD
Pomalidomide—ABCB1—gonad—hematologic cancer	8.92e-05	0.0108	CbGeAlD
Pomalidomide—ABCB1—blood—hematologic cancer	7.77e-05	0.00941	CbGeAlD
Pomalidomide—PTGS2—lymph node—hematologic cancer	7.54e-05	0.00912	CbGeAlD
Pomalidomide—ABCB1—bone marrow—hematologic cancer	7.52e-05	0.0091	CbGeAlD
Pomalidomide—ABCB1—lung—hematologic cancer	6.82e-05	0.00825	CbGeAlD
Pomalidomide—ABCB1—testis—hematologic cancer	6.43e-05	0.00778	CbGeAlD
Pomalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—hematologic cancer	6.02e-05	0.126	CbGdCrCtD
Pomalidomide—PTGS2—Fluticasone Propionate—Betamethasone—hematologic cancer	6.02e-05	0.126	CbGdCrCtD
Pomalidomide—Thalidomide—TNF—hematologic cancer	5.97e-05	0.0343	CrCbGaD
Pomalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—hematologic cancer	5.88e-05	0.124	CbGdCrCtD
Pomalidomide—ABCB1—lymph node—hematologic cancer	4.66e-05	0.00564	CbGeAlD
Pomalidomide—Lenalidomide—ABCB1—hematologic cancer	4.03e-05	0.0231	CrCbGaD
Pomalidomide—Dizziness—Irinotecan—hematologic cancer	6.83e-06	0.000119	CcSEcCtD
Pomalidomide—Body temperature increased—Etoposide—hematologic cancer	6.79e-06	0.000118	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—hematologic cancer	6.79e-06	0.000118	CcSEcCtD
Pomalidomide—Vertigo—Prednisone—hematologic cancer	6.78e-06	0.000118	CcSEcCtD
Pomalidomide—Vomiting—Vincristine—hematologic cancer	6.75e-06	0.000117	CcSEcCtD
Pomalidomide—Asthenia—Cisplatin—hematologic cancer	6.73e-06	0.000117	CcSEcCtD
Pomalidomide—Cardiac disorder—Methotrexate—hematologic cancer	6.73e-06	0.000117	CcSEcCtD
Pomalidomide—Fatigue—Triamcinolone—hematologic cancer	6.72e-06	0.000117	CcSEcCtD
Pomalidomide—Urinary tract disorder—Epirubicin—hematologic cancer	6.7e-06	0.000117	CcSEcCtD
Pomalidomide—Rash—Vincristine—hematologic cancer	6.69e-06	0.000116	CcSEcCtD
Pomalidomide—Dermatitis—Vincristine—hematologic cancer	6.68e-06	0.000116	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—hematologic cancer	6.68e-06	0.000116	CcSEcCtD
Pomalidomide—Pain—Triamcinolone—hematologic cancer	6.67e-06	0.000116	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—hematologic cancer	6.66e-06	0.000116	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—hematologic cancer	6.65e-06	0.000116	CcSEcCtD
Pomalidomide—Headache—Vincristine—hematologic cancer	6.65e-06	0.000116	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—hematologic cancer	6.61e-06	0.000115	CcSEcCtD
Pomalidomide—Nausea—Carmustine—hematologic cancer	6.6e-06	0.000115	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—hematologic cancer	6.59e-06	0.000115	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—hematologic cancer	6.57e-06	0.000114	CcSEcCtD
Pomalidomide—Vomiting—Mitoxantrone—hematologic cancer	6.57e-06	0.000114	CcSEcCtD
Pomalidomide—Vomiting—Irinotecan—hematologic cancer	6.57e-06	0.000114	CcSEcCtD
Pomalidomide—Nausea—Alitretinoin—hematologic cancer	6.54e-06	0.000114	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—hematologic cancer	6.53e-06	0.000114	CcSEcCtD
Pomalidomide—Rash—Mitoxantrone—hematologic cancer	6.52e-06	0.000113	CcSEcCtD
Pomalidomide—Rash—Irinotecan—hematologic cancer	6.52e-06	0.000113	CcSEcCtD
Pomalidomide—Dermatitis—Irinotecan—hematologic cancer	6.51e-06	0.000113	CcSEcCtD
Pomalidomide—Dermatitis—Mitoxantrone—hematologic cancer	6.51e-06	0.000113	CcSEcCtD
Pomalidomide—Chills—Methotrexate—hematologic cancer	6.5e-06	0.000113	CcSEcCtD
Pomalidomide—Headache—Mitoxantrone—hematologic cancer	6.47e-06	0.000113	CcSEcCtD
Pomalidomide—Headache—Irinotecan—hematologic cancer	6.47e-06	0.000113	CcSEcCtD
Pomalidomide—Nausea—Ifosfamide—hematologic cancer	6.46e-06	0.000113	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Betamethasone—hematologic cancer	6.44e-06	0.000112	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	6.44e-06	0.000112	CcSEcCtD
Pomalidomide—Arthralgia—Prednisone—hematologic cancer	6.43e-06	0.000112	CcSEcCtD
Pomalidomide—Feeling abnormal—Triamcinolone—hematologic cancer	6.42e-06	0.000112	CcSEcCtD
Pomalidomide—Diarrhoea—Cisplatin—hematologic cancer	6.42e-06	0.000112	CcSEcCtD
Pomalidomide—Anxiety—Prednisone—hematologic cancer	6.4e-06	0.000111	CcSEcCtD
Pomalidomide—Vomiting—Gemcitabine—hematologic cancer	6.4e-06	0.000111	CcSEcCtD
Pomalidomide—Insomnia—Betamethasone—hematologic cancer	6.4e-06	0.000111	CcSEcCtD
Pomalidomide—Insomnia—Dexamethasone—hematologic cancer	6.4e-06	0.000111	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.38e-06	0.000111	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—hematologic cancer	6.35e-06	0.00011	CcSEcCtD
Pomalidomide—Rash—Gemcitabine—hematologic cancer	6.35e-06	0.00011	CcSEcCtD
Pomalidomide—Dermatitis—Gemcitabine—hematologic cancer	6.34e-06	0.00011	CcSEcCtD
Pomalidomide—Hypersensitivity—Etoposide—hematologic cancer	6.33e-06	0.00011	CcSEcCtD
Pomalidomide—Malnutrition—Methotrexate—hematologic cancer	6.31e-06	0.00011	CcSEcCtD
Pomalidomide—Headache—Gemcitabine—hematologic cancer	6.31e-06	0.00011	CcSEcCtD
Pomalidomide—Nausea—Vincristine—hematologic cancer	6.3e-06	0.00011	CcSEcCtD
Pomalidomide—Cardiac disorder—Epirubicin—hematologic cancer	6.29e-06	0.00011	CcSEcCtD
Pomalidomide—Hypersensitivity—Prednisolone—hematologic cancer	6.25e-06	0.000109	CcSEcCtD
Pomalidomide—Urinary tract disorder—Doxorubicin—hematologic cancer	6.2e-06	0.000108	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—hematologic cancer	6.18e-06	0.000108	CcSEcCtD
Pomalidomide—Asthenia—Etoposide—hematologic cancer	6.17e-06	0.000107	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—hematologic cancer	6.17e-06	0.000107	CcSEcCtD
Pomalidomide—Body temperature increased—Triamcinolone—hematologic cancer	6.16e-06	0.000107	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—hematologic cancer	6.15e-06	0.000107	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—hematologic cancer	6.15e-06	0.000107	CcSEcCtD
Pomalidomide—Decreased appetite—Betamethasone—hematologic cancer	6.15e-06	0.000107	CcSEcCtD
Pomalidomide—Decreased appetite—Dexamethasone—hematologic cancer	6.15e-06	0.000107	CcSEcCtD
Pomalidomide—Nausea—Irinotecan—hematologic cancer	6.14e-06	0.000107	CcSEcCtD
Pomalidomide—Nausea—Mitoxantrone—hematologic cancer	6.14e-06	0.000107	CcSEcCtD
Pomalidomide—Infection—Prednisone—hematologic cancer	6.12e-06	0.000107	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—hematologic cancer	6.11e-06	0.000106	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.11e-06	0.000106	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.11e-06	0.000106	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—hematologic cancer	6.1e-06	0.000106	CcSEcCtD
Pomalidomide—Fatigue—Betamethasone—hematologic cancer	6.1e-06	0.000106	CcSEcCtD
Pomalidomide—Fatigue—Dexamethasone—hematologic cancer	6.1e-06	0.000106	CcSEcCtD
Pomalidomide—Chills—Epirubicin—hematologic cancer	6.09e-06	0.000106	CcSEcCtD
Pomalidomide—Pruritus—Etoposide—hematologic cancer	6.08e-06	0.000106	CcSEcCtD
Pomalidomide—Pain—Dexamethasone—hematologic cancer	6.05e-06	0.000105	CcSEcCtD
Pomalidomide—Pain—Betamethasone—hematologic cancer	6.05e-06	0.000105	CcSEcCtD
Pomalidomide—Nervous system disorder—Prednisone—hematologic cancer	6.04e-06	0.000105	CcSEcCtD
Pomalidomide—Skin disorder—Prednisone—hematologic cancer	5.98e-06	0.000104	CcSEcCtD
Pomalidomide—Nausea—Gemcitabine—hematologic cancer	5.98e-06	0.000104	CcSEcCtD
Pomalidomide—Vomiting—Cisplatin—hematologic cancer	5.97e-06	0.000104	CcSEcCtD
Pomalidomide—Hyperhidrosis—Prednisone—hematologic cancer	5.96e-06	0.000104	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—hematologic cancer	5.94e-06	0.000103	CcSEcCtD
Pomalidomide—Rash—Cisplatin—hematologic cancer	5.92e-06	0.000103	CcSEcCtD
Pomalidomide—Dermatitis—Cisplatin—hematologic cancer	5.91e-06	0.000103	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—hematologic cancer	5.9e-06	0.000103	CcSEcCtD
Pomalidomide—Diarrhoea—Etoposide—hematologic cancer	5.88e-06	0.000102	CcSEcCtD
Pomalidomide—Anaemia—Methotrexate—hematologic cancer	5.83e-06	0.000101	CcSEcCtD
Pomalidomide—Feeling abnormal—Betamethasone—hematologic cancer	5.83e-06	0.000101	CcSEcCtD
Pomalidomide—Feeling abnormal—Dexamethasone—hematologic cancer	5.83e-06	0.000101	CcSEcCtD
Pomalidomide—Cardiac disorder—Doxorubicin—hematologic cancer	5.82e-06	0.000101	CcSEcCtD
Pomalidomide—Hypersensitivity—Triamcinolone—hematologic cancer	5.74e-06	0.0001	CcSEcCtD
Pomalidomide—Back pain—Epirubicin—hematologic cancer	5.71e-06	9.94e-05	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—hematologic cancer	5.69e-06	9.91e-05	CcSEcCtD
Pomalidomide—Dizziness—Etoposide—hematologic cancer	5.68e-06	9.89e-05	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—hematologic cancer	5.68e-06	9.88e-05	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—hematologic cancer	5.67e-06	9.86e-05	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—hematologic cancer	5.66e-06	9.84e-05	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—hematologic cancer	5.65e-06	9.83e-05	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—hematologic cancer	5.63e-06	9.8e-05	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.61e-06	9.77e-05	CcSEcCtD
Pomalidomide—Dizziness—Prednisolone—hematologic cancer	5.61e-06	9.76e-05	CcSEcCtD
Pomalidomide—Asthenia—Triamcinolone—hematologic cancer	5.59e-06	9.74e-05	CcSEcCtD
Pomalidomide—Body temperature increased—Dexamethasone—hematologic cancer	5.59e-06	9.73e-05	CcSEcCtD
Pomalidomide—Body temperature increased—Betamethasone—hematologic cancer	5.59e-06	9.73e-05	CcSEcCtD
Pomalidomide—Nausea—Cisplatin—hematologic cancer	5.57e-06	9.7e-05	CcSEcCtD
Pomalidomide—Insomnia—Prednisone—hematologic cancer	5.57e-06	9.7e-05	CcSEcCtD
Pomalidomide—Pruritus—Triamcinolone—hematologic cancer	5.52e-06	9.6e-05	CcSEcCtD
Pomalidomide—Cough—Methotrexate—hematologic cancer	5.5e-06	9.58e-05	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—hematologic cancer	5.5e-06	9.57e-05	CcSEcCtD
Pomalidomide—Vomiting—Etoposide—hematologic cancer	5.47e-06	9.51e-05	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—hematologic cancer	5.46e-06	9.51e-05	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—hematologic cancer	5.46e-06	9.5e-05	CcSEcCtD
Pomalidomide—Rash—Etoposide—hematologic cancer	5.42e-06	9.43e-05	CcSEcCtD
Pomalidomide—Dermatitis—Etoposide—hematologic cancer	5.41e-06	9.42e-05	CcSEcCtD
Pomalidomide—Headache—Etoposide—hematologic cancer	5.38e-06	9.37e-05	CcSEcCtD
Pomalidomide—Arthralgia—Methotrexate—hematologic cancer	5.37e-06	9.35e-05	CcSEcCtD
Pomalidomide—Decreased appetite—Prednisone—hematologic cancer	5.36e-06	9.32e-05	CcSEcCtD
Pomalidomide—Rash—Prednisolone—hematologic cancer	5.35e-06	9.3e-05	CcSEcCtD
Pomalidomide—Dermatitis—Prednisolone—hematologic cancer	5.34e-06	9.29e-05	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.33e-06	9.28e-05	CcSEcCtD
Pomalidomide—Fatigue—Prednisone—hematologic cancer	5.31e-06	9.24e-05	CcSEcCtD
Pomalidomide—Headache—Prednisolone—hematologic cancer	5.31e-06	9.24e-05	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—hematologic cancer	5.3e-06	9.23e-05	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—hematologic cancer	5.28e-06	9.2e-05	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—hematologic cancer	5.28e-06	9.2e-05	CcSEcCtD
Pomalidomide—Constipation—Prednisone—hematologic cancer	5.27e-06	9.17e-05	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—hematologic cancer	5.25e-06	9.14e-05	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—hematologic cancer	5.19e-06	9.03e-05	CcSEcCtD
Pomalidomide—Dizziness—Triamcinolone—hematologic cancer	5.16e-06	8.97e-05	CcSEcCtD
Pomalidomide—Cough—Epirubicin—hematologic cancer	5.15e-06	8.97e-05	CcSEcCtD
Pomalidomide—Infection—Methotrexate—hematologic cancer	5.11e-06	8.9e-05	CcSEcCtD
Pomalidomide—Nausea—Etoposide—hematologic cancer	5.11e-06	8.89e-05	CcSEcCtD
Pomalidomide—Feeling abnormal—Prednisone—hematologic cancer	5.08e-06	8.84e-05	CcSEcCtD
Pomalidomide—Asthenia—Dexamethasone—hematologic cancer	5.08e-06	8.83e-05	CcSEcCtD
Pomalidomide—Asthenia—Betamethasone—hematologic cancer	5.08e-06	8.83e-05	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—hematologic cancer	5.05e-06	8.79e-05	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—hematologic cancer	5.05e-06	8.79e-05	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—hematologic cancer	5.04e-06	8.77e-05	CcSEcCtD
Pomalidomide—Nausea—Prednisolone—hematologic cancer	5.04e-06	8.76e-05	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—hematologic cancer	5.03e-06	8.75e-05	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—hematologic cancer	5.01e-06	8.72e-05	CcSEcCtD
Pomalidomide—Pruritus—Dexamethasone—hematologic cancer	5e-06	8.71e-05	CcSEcCtD
Pomalidomide—Pruritus—Betamethasone—hematologic cancer	5e-06	8.71e-05	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—hematologic cancer	5e-06	8.7e-05	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.99e-06	8.69e-05	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—hematologic cancer	4.98e-06	8.66e-05	CcSEcCtD
Pomalidomide—Vomiting—Triamcinolone—hematologic cancer	4.96e-06	8.63e-05	CcSEcCtD
Pomalidomide—Rash—Triamcinolone—hematologic cancer	4.92e-06	8.56e-05	CcSEcCtD
Pomalidomide—Dermatitis—Triamcinolone—hematologic cancer	4.91e-06	8.55e-05	CcSEcCtD
Pomalidomide—Vertigo—Doxorubicin—hematologic cancer	4.91e-06	8.54e-05	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—hematologic cancer	4.89e-06	8.51e-05	CcSEcCtD
Pomalidomide—Headache—Triamcinolone—hematologic cancer	4.88e-06	8.5e-05	CcSEcCtD
Pomalidomide—Body temperature increased—Prednisone—hematologic cancer	4.87e-06	8.48e-05	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—hematologic cancer	4.86e-06	8.46e-05	CcSEcCtD
Pomalidomide—Diarrhoea—Dexamethasone—hematologic cancer	4.84e-06	8.42e-05	CcSEcCtD
Pomalidomide—Diarrhoea—Betamethasone—hematologic cancer	4.84e-06	8.42e-05	CcSEcCtD
Pomalidomide—Infection—Epirubicin—hematologic cancer	4.79e-06	8.33e-05	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—hematologic cancer	4.77e-06	8.3e-05	CcSEcCtD
Pomalidomide—Nervous system disorder—Epirubicin—hematologic cancer	4.73e-06	8.22e-05	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—hematologic cancer	4.72e-06	8.21e-05	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.69e-06	8.16e-05	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—hematologic cancer	4.68e-06	8.15e-05	CcSEcCtD
Pomalidomide—Dizziness—Betamethasone—hematologic cancer	4.68e-06	8.14e-05	CcSEcCtD
Pomalidomide—Dizziness—Dexamethasone—hematologic cancer	4.68e-06	8.14e-05	CcSEcCtD
Pomalidomide—Hyperhidrosis—Epirubicin—hematologic cancer	4.66e-06	8.11e-05	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—hematologic cancer	4.66e-06	8.1e-05	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—hematologic cancer	4.65e-06	8.09e-05	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—hematologic cancer	4.63e-06	8.07e-05	CcSEcCtD
Pomalidomide—Nausea—Triamcinolone—hematologic cancer	4.63e-06	8.06e-05	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.62e-06	8.04e-05	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—hematologic cancer	4.59e-06	7.99e-05	CcSEcCtD
Pomalidomide—Hypersensitivity—Prednisone—hematologic cancer	4.54e-06	7.9e-05	CcSEcCtD
Pomalidomide—Vomiting—Betamethasone—hematologic cancer	4.5e-06	7.83e-05	CcSEcCtD
Pomalidomide—Vomiting—Dexamethasone—hematologic cancer	4.5e-06	7.83e-05	CcSEcCtD
Pomalidomide—Confusional state—Doxorubicin—hematologic cancer	4.5e-06	7.82e-05	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—hematologic cancer	4.48e-06	7.79e-05	CcSEcCtD
Pomalidomide—Rash—Betamethasone—hematologic cancer	4.46e-06	7.76e-05	CcSEcCtD
Pomalidomide—Rash—Dexamethasone—hematologic cancer	4.46e-06	7.76e-05	CcSEcCtD
Pomalidomide—Dermatitis—Dexamethasone—hematologic cancer	4.46e-06	7.76e-05	CcSEcCtD
Pomalidomide—Dermatitis—Betamethasone—hematologic cancer	4.46e-06	7.76e-05	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.44e-06	7.74e-05	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—hematologic cancer	4.44e-06	7.73e-05	CcSEcCtD
Pomalidomide—Headache—Dexamethasone—hematologic cancer	4.43e-06	7.71e-05	CcSEcCtD
Pomalidomide—Headache—Betamethasone—hematologic cancer	4.43e-06	7.71e-05	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—hematologic cancer	4.43e-06	7.71e-05	CcSEcCtD
Pomalidomide—Asthenia—Prednisone—hematologic cancer	4.42e-06	7.69e-05	CcSEcCtD
Pomalidomide—Pain—Methotrexate—hematologic cancer	4.4e-06	7.66e-05	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.39e-06	7.64e-05	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—hematologic cancer	4.37e-06	7.61e-05	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—hematologic cancer	4.36e-06	7.6e-05	CcSEcCtD
Pomalidomide—Pruritus—Prednisone—hematologic cancer	4.36e-06	7.59e-05	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—hematologic cancer	4.36e-06	7.58e-05	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—hematologic cancer	4.33e-06	7.54e-05	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—hematologic cancer	4.31e-06	7.5e-05	CcSEcCtD
Pomalidomide—Dyspnoea—Epirubicin—hematologic cancer	4.3e-06	7.48e-05	CcSEcCtD
Pomalidomide—Feeling abnormal—Methotrexate—hematologic cancer	4.24e-06	7.38e-05	CcSEcCtD
Pomalidomide—Diarrhoea—Prednisone—hematologic cancer	4.22e-06	7.34e-05	CcSEcCtD
Pomalidomide—Nausea—Betamethasone—hematologic cancer	4.2e-06	7.31e-05	CcSEcCtD
Pomalidomide—Nausea—Dexamethasone—hematologic cancer	4.2e-06	7.31e-05	CcSEcCtD
Pomalidomide—Decreased appetite—Epirubicin—hematologic cancer	4.19e-06	7.29e-05	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.16e-06	7.24e-05	CcSEcCtD
Pomalidomide—Fatigue—Epirubicin—hematologic cancer	4.15e-06	7.23e-05	CcSEcCtD
Pomalidomide—Pain—Epirubicin—hematologic cancer	4.12e-06	7.17e-05	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—hematologic cancer	4.12e-06	7.17e-05	CcSEcCtD
Pomalidomide—Dizziness—Prednisone—hematologic cancer	4.07e-06	7.09e-05	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—hematologic cancer	4.07e-06	7.08e-05	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.06e-06	7.07e-05	CcSEcCtD
Pomalidomide—Insomnia—Doxorubicin—hematologic cancer	4.03e-06	7.02e-05	CcSEcCtD
Pomalidomide—Dyspnoea—Doxorubicin—hematologic cancer	3.97e-06	6.92e-05	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—hematologic cancer	3.97e-06	6.91e-05	CcSEcCtD
Pomalidomide—Vomiting—Prednisone—hematologic cancer	3.92e-06	6.82e-05	CcSEcCtD
Pomalidomide—Rash—Prednisone—hematologic cancer	3.88e-06	6.76e-05	CcSEcCtD
Pomalidomide—Dermatitis—Prednisone—hematologic cancer	3.88e-06	6.75e-05	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—hematologic cancer	3.88e-06	6.74e-05	CcSEcCtD
Pomalidomide—Headache—Prednisone—hematologic cancer	3.86e-06	6.72e-05	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.85e-06	6.7e-05	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—hematologic cancer	3.84e-06	6.69e-05	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—hematologic cancer	3.81e-06	6.63e-05	CcSEcCtD
Pomalidomide—Constipation—Doxorubicin—hematologic cancer	3.81e-06	6.63e-05	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—hematologic cancer	3.81e-06	6.63e-05	CcSEcCtD
Pomalidomide—Hypersensitivity—Methotrexate—hematologic cancer	3.79e-06	6.6e-05	CcSEcCtD
Pomalidomide—Asthenia—Methotrexate—hematologic cancer	3.69e-06	6.43e-05	CcSEcCtD
Pomalidomide—Feeling abnormal—Doxorubicin—hematologic cancer	3.67e-06	6.39e-05	CcSEcCtD
Pomalidomide—Nausea—Prednisone—hematologic cancer	3.66e-06	6.37e-05	CcSEcCtD
Pomalidomide—Pruritus—Methotrexate—hematologic cancer	3.64e-06	6.34e-05	CcSEcCtD
Pomalidomide—Hypersensitivity—Epirubicin—hematologic cancer	3.55e-06	6.18e-05	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—hematologic cancer	3.52e-06	6.13e-05	CcSEcCtD
Pomalidomide—Diarrhoea—Methotrexate—hematologic cancer	3.52e-06	6.13e-05	CcSEcCtD
Pomalidomide—Asthenia—Epirubicin—hematologic cancer	3.46e-06	6.02e-05	CcSEcCtD
Pomalidomide—Pruritus—Epirubicin—hematologic cancer	3.41e-06	5.93e-05	CcSEcCtD
Pomalidomide—Dizziness—Methotrexate—hematologic cancer	3.4e-06	5.93e-05	CcSEcCtD
Pomalidomide—Diarrhoea—Epirubicin—hematologic cancer	3.3e-06	5.74e-05	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—hematologic cancer	3.28e-06	5.72e-05	CcSEcCtD
Pomalidomide—Vomiting—Methotrexate—hematologic cancer	3.27e-06	5.7e-05	CcSEcCtD
Pomalidomide—Rash—Methotrexate—hematologic cancer	3.25e-06	5.65e-05	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—hematologic cancer	3.24e-06	5.64e-05	CcSEcCtD
Pomalidomide—Headache—Methotrexate—hematologic cancer	3.23e-06	5.61e-05	CcSEcCtD
Pomalidomide—Asthenia—Doxorubicin—hematologic cancer	3.2e-06	5.57e-05	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—hematologic cancer	3.19e-06	5.55e-05	CcSEcCtD
Pomalidomide—Pruritus—Doxorubicin—hematologic cancer	3.15e-06	5.49e-05	CcSEcCtD
Pomalidomide—Vomiting—Epirubicin—hematologic cancer	3.06e-06	5.33e-05	CcSEcCtD
Pomalidomide—Nausea—Methotrexate—hematologic cancer	3.06e-06	5.32e-05	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—hematologic cancer	3.05e-06	5.31e-05	CcSEcCtD
Pomalidomide—Rash—Epirubicin—hematologic cancer	3.04e-06	5.29e-05	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—hematologic cancer	3.04e-06	5.28e-05	CcSEcCtD
Pomalidomide—Headache—Epirubicin—hematologic cancer	3.02e-06	5.25e-05	CcSEcCtD
Pomalidomide—Dizziness—Doxorubicin—hematologic cancer	2.95e-06	5.13e-05	CcSEcCtD
Pomalidomide—Nausea—Epirubicin—hematologic cancer	2.86e-06	4.98e-05	CcSEcCtD
Pomalidomide—Vomiting—Doxorubicin—hematologic cancer	2.83e-06	4.93e-05	CcSEcCtD
Pomalidomide—Rash—Doxorubicin—hematologic cancer	2.81e-06	4.89e-05	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—hematologic cancer	2.81e-06	4.89e-05	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—hematologic cancer	2.79e-06	4.86e-05	CcSEcCtD
Pomalidomide—Nausea—Doxorubicin—hematologic cancer	2.65e-06	4.61e-05	CcSEcCtD
Pomalidomide—CYP3A4—Metabolism—HDC—hematologic cancer	1.78e-06	6.36e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FBXW7—hematologic cancer	1.77e-06	6.33e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	1.76e-06	6.31e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ARNTL—hematologic cancer	1.75e-06	6.25e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HDAC2—hematologic cancer	1.73e-06	6.21e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CXCR4—hematologic cancer	1.73e-06	6.21e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTT1—hematologic cancer	1.73e-06	6.19e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD44—hematologic cancer	1.71e-06	6.14e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	1.71e-06	6.14e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	1.71e-06	6.12e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.7e-06	6.09e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CA9—hematologic cancer	1.7e-06	6.08e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ACP5—hematologic cancer	1.7e-06	6.08e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CBL—hematologic cancer	1.69e-06	6.05e-05	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KRAS—hematologic cancer	1.69e-06	6.05e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SDC1—hematologic cancer	1.69e-06	6.05e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NCOR2—hematologic cancer	1.68e-06	6e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	1.68e-06	6e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CDA—hematologic cancer	1.62e-06	5.82e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.61e-06	5.78e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HSP90AA1—hematologic cancer	1.61e-06	5.77e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—IDH1—hematologic cancer	1.6e-06	5.72e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	1.6e-06	5.72e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—FHL2—hematologic cancer	1.59e-06	5.71e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.59e-06	5.7e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	1.58e-06	5.67e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ABCC3—hematologic cancer	1.58e-06	5.66e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TXN—hematologic cancer	1.58e-06	5.66e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTO1—hematologic cancer	1.58e-06	5.66e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AGRN—hematologic cancer	1.56e-06	5.6e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PC—hematologic cancer	1.56e-06	5.6e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT1—hematologic cancer	1.55e-06	5.57e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SPHK1—hematologic cancer	1.55e-06	5.53e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.52e-06	5.45e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.51e-06	5.41e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GBA—hematologic cancer	1.51e-06	5.41e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—UGT1A1—hematologic cancer	1.48e-06	5.32e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—IDH2—hematologic cancer	1.48e-06	5.31e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HMMR—hematologic cancer	1.48e-06	5.31e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	1.45e-06	5.21e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GRB2—hematologic cancer	1.45e-06	5.21e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFA—hematologic cancer	1.45e-06	5.19e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC22A1—hematologic cancer	1.44e-06	5.17e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CRABP1—hematologic cancer	1.44e-06	5.17e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NQO1—hematologic cancer	1.44e-06	5.14e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CD44—hematologic cancer	1.44e-06	5.14e-05	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—hematologic cancer	1.44e-06	5.14e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KITLG—hematologic cancer	1.43e-06	5.12e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALOX5—hematologic cancer	1.41e-06	5.04e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	1.41e-06	5.04e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.41e-06	5.03e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.4e-06	5.01e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT5A—hematologic cancer	1.4e-06	5e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ARNTL—hematologic cancer	1.39e-06	4.99e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN2B—hematologic cancer	1.39e-06	4.96e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTAP—hematologic cancer	1.38e-06	4.95e-05	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—hematologic cancer	1.37e-06	4.92e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NUP98—hematologic cancer	1.36e-06	4.88e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYCS—hematologic cancer	1.36e-06	4.86e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CA9—hematologic cancer	1.36e-06	4.86e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ACP5—hematologic cancer	1.36e-06	4.86e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HSP90AA1—hematologic cancer	1.35e-06	4.83e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD86—hematologic cancer	1.34e-06	4.8e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NCOR2—hematologic cancer	1.34e-06	4.79e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ADCY7—hematologic cancer	1.32e-06	4.74e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NCOA3—hematologic cancer	1.32e-06	4.74e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HES1—hematologic cancer	1.32e-06	4.73e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NUP214—hematologic cancer	1.31e-06	4.71e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NCOR1—hematologic cancer	1.31e-06	4.71e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF1—hematologic cancer	1.3e-06	4.65e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTR—hematologic cancer	1.29e-06	4.61e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ABCG2—hematologic cancer	1.29e-06	4.61e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FOXO1—hematologic cancer	1.28e-06	4.59e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFRB—hematologic cancer	1.28e-06	4.58e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—IDH1—hematologic cancer	1.28e-06	4.57e-05	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—hematologic cancer	1.27e-06	4.54e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ENO2—hematologic cancer	1.26e-06	4.52e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCC3—hematologic cancer	1.26e-06	4.51e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TXN—hematologic cancer	1.26e-06	4.51e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTO1—hematologic cancer	1.26e-06	4.51e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFRA—hematologic cancer	1.26e-06	4.51e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PRKCG—hematologic cancer	1.25e-06	4.49e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—JAK1—hematologic cancer	1.25e-06	4.49e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SPHK1—hematologic cancer	1.23e-06	4.42e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—FHL2—hematologic cancer	1.23e-06	4.41e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTT1—hematologic cancer	1.22e-06	4.39e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.21e-06	4.35e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AGRN—hematologic cancer	1.21e-06	4.32e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTP1—hematologic cancer	1.2e-06	4.29e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SDC1—hematologic cancer	1.2e-06	4.29e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	1.19e-06	4.26e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—UGT1A1—hematologic cancer	1.19e-06	4.25e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—hematologic cancer	1.16e-06	4.16e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.16e-06	4.15e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HLA-A—hematologic cancer	1.16e-06	4.15e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TERT—hematologic cancer	1.16e-06	4.15e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC22A1—hematologic cancer	1.15e-06	4.13e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CRABP1—hematologic cancer	1.15e-06	4.13e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.15e-06	4.11e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—IDH2—hematologic cancer	1.14e-06	4.1e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HMMR—hematologic cancer	1.14e-06	4.1e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCB1—hematologic cancer	1.13e-06	4.06e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PDGFB—hematologic cancer	1.13e-06	4.05e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALOX5—hematologic cancer	1.12e-06	4.02e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TSC2—hematologic cancer	1.1e-06	3.96e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTM1—hematologic cancer	1.1e-06	3.94e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NCOR1—hematologic cancer	1.1e-06	3.94e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NUP98—hematologic cancer	1.09e-06	3.9e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.08e-06	3.85e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	1.07e-06	3.84e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR3—hematologic cancer	1.06e-06	3.81e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ADCY7—hematologic cancer	1.06e-06	3.78e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NCOA3—hematologic cancer	1.06e-06	3.78e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NUP214—hematologic cancer	1.05e-06	3.76e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CA9—hematologic cancer	1.05e-06	3.75e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ACP5—hematologic cancer	1.05e-06	3.75e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.04e-06	3.72e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.03e-06	3.7e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCG2—hematologic cancer	1.03e-06	3.68e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTR—hematologic cancer	1.03e-06	3.68e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CD44—hematologic cancer	1.02e-06	3.64e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NQO1—hematologic cancer	1.02e-06	3.64e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ENO2—hematologic cancer	1.01e-06	3.61e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BAD—hematologic cancer	1.01e-06	3.61e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOTCH1—hematologic cancer	9.98e-07	3.57e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—IDH1—hematologic cancer	9.84e-07	3.52e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTT1—hematologic cancer	9.78e-07	3.5e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD80—hematologic cancer	9.77e-07	3.5e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KIT—hematologic cancer	9.76e-07	3.49e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCC3—hematologic cancer	9.73e-07	3.48e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TXN—hematologic cancer	9.73e-07	3.48e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTO1—hematologic cancer	9.73e-07	3.48e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—hematologic cancer	9.72e-07	3.48e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYCS—hematologic cancer	9.63e-07	3.45e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	9.63e-07	3.45e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTPN11—hematologic cancer	9.59e-07	3.43e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HSP90AA1—hematologic cancer	9.57e-07	3.43e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SDC1—hematologic cancer	9.56e-07	3.42e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SPHK1—hematologic cancer	9.52e-07	3.41e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CREB1—hematologic cancer	9.29e-07	3.33e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BRAF—hematologic cancer	9.17e-07	3.28e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—UGT1A1—hematologic cancer	9.15e-07	3.28e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	9.13e-07	3.27e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6R—hematologic cancer	9.06e-07	3.24e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CREBBP—hematologic cancer	9.05e-07	3.24e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	9.01e-07	3.23e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CRABP1—hematologic cancer	8.9e-07	3.19e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC22A1—hematologic cancer	8.9e-07	3.19e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALOX5—hematologic cancer	8.67e-07	3.11e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAP2K1—hematologic cancer	8.63e-07	3.09e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	8.62e-07	3.09e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CD—hematologic cancer	8.58e-07	3.07e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	8.57e-07	3.07e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTP1—hematologic cancer	8.49e-07	3.04e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NUP98—hematologic cancer	8.4e-07	3.01e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGF2—hematologic cancer	8.21e-07	2.94e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CG—hematologic cancer	8.17e-07	2.93e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ADCY7—hematologic cancer	8.15e-07	2.92e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NCOA3—hematologic cancer	8.15e-07	2.92e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NQO1—hematologic cancer	8.12e-07	2.91e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CD44—hematologic cancer	8.12e-07	2.91e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3R1—hematologic cancer	8.1e-07	2.9e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NUP214—hematologic cancer	8.1e-07	2.9e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	7.96e-07	2.85e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCG2—hematologic cancer	7.93e-07	2.84e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTR—hematologic cancer	7.93e-07	2.84e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—JAK2—hematologic cancer	7.87e-07	2.82e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NCOR1—hematologic cancer	7.8e-07	2.79e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTM1—hematologic cancer	7.8e-07	2.79e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ENO2—hematologic cancer	7.78e-07	2.79e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYCS—hematologic cancer	7.69e-07	2.75e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MDM2—hematologic cancer	7.68e-07	2.75e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	7.64e-07	2.74e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CREBBP—hematologic cancer	7.58e-07	2.71e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTT1—hematologic cancer	7.54e-07	2.7e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CB—hematologic cancer	7.48e-07	2.68e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTOR—hematologic cancer	7.48e-07	2.68e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CD4—hematologic cancer	7.46e-07	2.67e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SDC1—hematologic cancer	7.37e-07	2.64e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CD—hematologic cancer	7.18e-07	2.57e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ALB—hematologic cancer	7.09e-07	2.54e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1B—hematologic cancer	7.02e-07	2.51e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—hematologic cancer	6.89e-07	2.47e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	6.87e-07	2.46e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3R1—hematologic cancer	6.78e-07	2.43e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTP1—hematologic cancer	6.78e-07	2.43e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	6.56e-07	2.35e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1A—hematologic cancer	6.47e-07	2.32e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTEN—hematologic cancer	6.46e-07	2.31e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCB1—hematologic cancer	6.41e-07	2.3e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CD44—hematologic cancer	6.27e-07	2.25e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NQO1—hematologic cancer	6.27e-07	2.25e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CB—hematologic cancer	6.26e-07	2.24e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTM1—hematologic cancer	6.23e-07	2.23e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NCOR1—hematologic cancer	6.23e-07	2.23e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EP300—hematologic cancer	6.16e-07	2.21e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SRC—hematologic cancer	5.99e-07	2.15e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYCS—hematologic cancer	5.93e-07	2.12e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	5.9e-07	2.11e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CG—hematologic cancer	5.79e-07	2.07e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—STAT3—hematologic cancer	5.78e-07	2.07e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NRAS—hematologic cancer	5.76e-07	2.06e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MAPK3—hematologic cancer	5.52e-07	1.98e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—hematologic cancer	5.5e-07	1.97e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTEN—hematologic cancer	5.41e-07	1.94e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CREBBP—hematologic cancer	5.37e-07	1.92e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—hematologic cancer	5.37e-07	1.92e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—hematologic cancer	5.36e-07	1.92e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTP1—hematologic cancer	5.23e-07	1.87e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—EP300—hematologic cancer	5.16e-07	1.85e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CD—hematologic cancer	5.09e-07	1.82e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ALB—hematologic cancer	5.03e-07	1.8e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—hematologic cancer	4.96e-07	1.78e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCB1—hematologic cancer	4.95e-07	1.77e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.85e-07	1.74e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3R1—hematologic cancer	4.81e-07	1.72e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NCOR1—hematologic cancer	4.81e-07	1.72e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTM1—hematologic cancer	4.81e-07	1.72e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CG—hematologic cancer	4.62e-07	1.66e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PIK3CA—hematologic cancer	4.56e-07	1.63e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CB—hematologic cancer	4.44e-07	1.59e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CREBBP—hematologic cancer	4.29e-07	1.54e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—hematologic cancer	4.25e-07	1.52e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—hematologic cancer	4.22e-07	1.51e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CD—hematologic cancer	4.06e-07	1.46e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—hematologic cancer	4.04e-07	1.45e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ALB—hematologic cancer	4.01e-07	1.44e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3R1—hematologic cancer	3.84e-07	1.37e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTEN—hematologic cancer	3.84e-07	1.37e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PIK3CA—hematologic cancer	3.82e-07	1.37e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—hematologic cancer	3.72e-07	1.33e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—EP300—hematologic cancer	3.66e-07	1.31e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.57e-07	1.28e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CB—hematologic cancer	3.54e-07	1.27e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.31e-07	1.18e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CD—hematologic cancer	3.14e-07	1.12e-05	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—hematologic cancer	3.12e-07	1.12e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ALB—hematologic cancer	3.1e-07	1.11e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTEN—hematologic cancer	3.06e-07	1.1e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.96e-07	1.06e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—EP300—hematologic cancer	2.92e-07	1.05e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.73e-07	9.79e-06	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PIK3CA—hematologic cancer	2.71e-07	9.69e-06	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTEN—hematologic cancer	2.36e-07	8.46e-06	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—EP300—hematologic cancer	2.25e-07	8.07e-06	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—hematologic cancer	2.21e-07	7.91e-06	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PIK3CA—hematologic cancer	2.16e-07	7.73e-06	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—hematologic cancer	1.76e-07	6.32e-06	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.67e-07	5.97e-06	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—hematologic cancer	1.36e-07	4.88e-06	CbGpPWpGaD
